Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 25, 2022

Association of PD-L1 Expression and Other Variables With Benefit From ICI Therapy in Advanced Gastroesophageal Cancer

JAMA Oncology

 

Additional Info

JAMA Oncology
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials
JAMA Oncol 2022 Aug 25;[EPub Ahead of Print], HH Yoon, Z Jin, O Kour, LA Kankeu Fonkoua, K Shitara, MK Gibson, LJ Prokop, M Moehler, YK Kang, Q Shi, JA Ajani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading